Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing Among Multidrug-Resistant Tuberculosis Patients in Shanghai

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2016 Sep 22

PMID 27652260

Citations 10

Authors

Yong Chen

Zhengan Yuan

Xin Shen

Jie Wu

Zheyuan Wu

Biao Xu

Affiliations

Soon will be listed here.

Abstract

Introduction. Second-line antituberculosis drugs (SLDs) are used for treating multidrug-resistant tuberculosis (MDR-TB). Prolonged delays before confirming MDR-TB with drug susceptibility testing (DST) could result in transmission of drug-resistant strains and inappropriate use of SLDs, thereby increasing the risk of resistance to SLDs. This study investigated the diagnostic delay in DST and prevalence of baseline SLD resistance in Shanghai and described the distribution of SLD resistance with varied delays to DST. Methods. All registered patients from 2011 to 2013 in Shanghai were enrolled. Susceptibility to ofloxacin, amikacin, kanamycin, and capreomycin was tested. Total delay in DST completion was measured from the onset of symptoms to reporting DST results. Results. Resistance to SLDs was tested in 217 of the 276 MDR-TB strains, with 118 (54.4%) being resistant to at least one of the four SLDs. The median total delay in DST was 136 days. Patients with delay longer than median days were roughly twice more likely to have resistance to at least one SLD (OR 2.22, 95% CI 1.19-4.11). Conclusions. During prolonged delay in DST, primary and acquired resistance to SLDs might occur more frequently. Rapid diagnosis of MDR-TB, improved nosocomial infection controls, and regulated treatment are imperative to prevent SLD resistance.

Citing Articles

Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center.

Chand A, Basnet A, Maharjan B, Rai G, Joshi Y, Bhatt L PLoS One. 2024; 19(5):e0301210.

PMID: 38709710 PMC: 11073693. DOI: 10.1371/journal.pone.0301210.

Time to Treatment and Risk Factors for Unsuccessful Treatment Outcomes among People Who Started Second-Line Treatment for Rifampicin-Resistant or Multi-Drug-Resistant Tuberculosis in the Kyrgyz Republic, 2021.

Kyrbashov B, Kulzhabaeva A, Kadyrov A, Toktogonova A, Timire C, Satyanarayana S Trop Med Infect Dis. 2023; 8(8).

PMID: 37624346 PMC: 10459505. DOI: 10.3390/tropicalmed8080407.

Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems.

van Staden D, Haynes R, Viljoen J Antibiotics (Basel). 2022; 11(6).

PMID: 35740212 PMC: 9219976. DOI: 10.3390/antibiotics11060806.

Direct detection of resistance to fluoroquinolones/SLIDs in sputum specimen by GenoType MTBDRsl v.2.0 assay A study from Eastern Uttar Pradesh, India.

Singh K, Kumari R, Gupta S, Tripathi R, Srivastava A, Shakya V Ann Clin Microbiol Antimicrob. 2021; 20(1):56.

PMID: 34446022 PMC: 8394194. DOI: 10.1186/s12941-021-00463-6.

Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis.

Ernest J, Sarathy J, Wang N, Kaya F, Zimmerman M, Strydom N Antimicrob Agents Chemother. 2021; 65(10):e0050621.

PMID: 34252307 PMC: 8448094. DOI: 10.1128/AAC.00506-21.

References

Chen T, Lu P, Lin C, Lin W, Chen Y . Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011; 15(3):e211-6. DOI: 10.1016/j.ijid.2010.11.008. View

Dheda K, Gumbo T, Gandhi N, Murray M, Theron G, Udwadia Z . Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014; 2(4):321-38. PMC: 5526327. DOI: 10.1016/S2213-2600(14)70031-1. View

Hu Y, Mathema B, Zhao Q, Chen L, Lu W, Wang W . Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China. Clin Microbiol Infect. 2015; 21(12):1093.e9-1093.e18. DOI: 10.1016/j.cmi.2015.08.023. View

Streicher E, Muller B, Chihota V, Mlambo C, Tait M, Pillay M . Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol. 2011; 12(4):686-94. DOI: 10.1016/j.meegid.2011.07.019. View

Singla R, Sarin R, Khalid U, Mathuria K, Singla N, Jaiswal A . Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis. 2009; 13(8):976-81. View

Dooley K, Golub J, Goes F, Merz W, Sterling T . Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis. 2002; 34(12):1607-12. DOI: 10.1086/340618. View

Yu M, Wu M, Jou R . Extensively drug-resistant tuberculosis, Taiwan. Emerg Infect Dis. 2008; 14(5):849-50. PMC: 2600264. DOI: 10.3201/eid1405.071398. View

Bastos M, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung C . Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014; 59(10):1364-74. PMC: 4296130. DOI: 10.1093/cid/ciu619. View

Escombe A, Oeser C, Gilman R, Navincopa M, Ticona E, Pan W . Natural ventilation for the prevention of airborne contagion. PLoS Med. 2007; 4(2):e68. PMC: 1808096. DOI: 10.1371/journal.pmed.0040068. View

10.

Li X, Zhang Y, Shen X, Shen G, Gui X, Sun B . Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis. 2007; 195(6):864-9. DOI: 10.1086/511985. View

11.

Becerra M, Appleton S, Franke M, Chalco K, Arteaga F, Bayona J . Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2010; 377(9760):147-52. DOI: 10.1016/S0140-6736(10)61972-1. View

12.

Gandhi N, Nunn P, Dheda K, Schaaf H, Zignol M, van Soolingen D . Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010; 375(9728):1830-43. DOI: 10.1016/S0140-6736(10)60410-2. View

13.

Falzon D, Gandhi N, Migliori G, Sotgiu G, Cox H, Holtz T . Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2012; 42(1):156-68. PMC: 4487776. DOI: 10.1183/09031936.00134712. View

14.

Zhang X, Yin J, Li H, Li S, Walley J, Zou G . Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study. Trop Med Int Health. 2015; 20(11):1431-1437. DOI: 10.1111/tmi.12566. View

15.

Jeon C, Calver A, Victor T, Warren R, Shin S, Murray M . Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int J Tuberc Lung Dis. 2011; 15(1):77-83. View

16.

Cox H, Sibilia K, Feuerriegel S, Kalon S, Polonsky J, Khamraev A . Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med. 2008; 359(22):2398-400. DOI: 10.1056/NEJMc0805644. View

17.

Ioerger T, Feng Y, Chen X, Dobos K, Victor T, Streicher E . The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics. 2010; 11:670. PMC: 3091785. DOI: 10.1186/1471-2164-11-670. View

18.

Calver A, Falmer A, Murray M, Strauss O, Streicher E, Hanekom M . Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis. 2010; 16(2):264-71. PMC: 2958014. DOI: 10.3201/eid1602.090968. View

19.

Zhao Y, Xu S, Wang L, Chin D, Wang S, Jiang G . National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012; 366(23):2161-70. DOI: 10.1056/NEJMoa1108789. View

20.

Sreeramareddy C, Panduru K, Menten J, van den Ende J . Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis. 2009; 9:91. PMC: 2702369. DOI: 10.1186/1471-2334-9-91. View